GT BIOPHARMA, INC. (GTBP) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2021-09-30..
Gross margin
Overview →Financial period ending 2021-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2021-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 0.00 USD | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2021-09-30 | (m) | $0.00 | (m) | (m) |
| 2021-06-30 | (m) | $0.00 | (m) | (m) |
| 2021-03-31 | (m) | $0.00 | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-06-30 | $0.00 | $0.00 | $0.00 | (m) |
| 2018-03-31 | $0.00 | $0.00 | $0.00 | (m) |
| 2017-12-31 | $0.00 | $0.00 | $0.00 | (m) |
| 2017-09-30 | $0.00 | $0.00 | $0.00 | (m) |
| 2017-06-30 | $0.00 | $0.00 | $0.00 | (m) |
| 2017-03-31 | $0.00 | $0.00 | $0.00 | (m) |
| 2016-12-31 | $0.00 | $0.00 | $0.00 | (m) |
| 2016-09-30 | $0.00 | $0.00 | $0.00 | (m) |
| 2016-06-30 | $0.00 | $0.00 | $0.00 | (m) |
| 2016-03-31 | $20.00K | $20.00K | $0.00 | 100.00% |
| 2015-12-31 | $27.00K | $27.00K | $0.00 | 100.00% |
| 2015-09-30 | $25.00K | $60.00K | $35.00K | 41.67% |
| 2015-06-30 | $23.00K | $63.00K | $40.00K | 36.51% |
| 2015-03-31 | $11.00K | $68.00K | $57.00K | 16.18% |
| 2014-12-31 | $4.00K | $61.00K | $57.00K | 6.56% |
| 2014-09-30 | $25.00K | $69.00K | $44.00K | 36.23% |
| 2014-06-30 | $87.00K | $249.00K | $162.00K | 34.94% |
| 2014-03-31 | $123.00K | $280.00K | $157.00K | 43.93% |
| 2013-12-31 | $142.00K | $368.00K | $226.00K | 38.59% |
| 2013-09-30 | $281.00K | $546.00K | $265.00K | 51.47% |
| 2013-06-30 | $310.00K | $483.00K | $174.00K | 64.18% |
| 2013-03-31 | $267.00K | $429.00K | $162.00K | 62.24% |
| 2012-12-31 | $248.00K | $342.00K | $94.00K | 72.51% |
| 2012-09-30 | $93.00K | $126.00K | $33.00K | 73.81% |
| 2012-06-30 | $-2.00K | $7.00K | $9.00K | -28.57% |
| 2012-03-31 | (m) | $7.00K | $24.00K | (m) |
| 2011-12-31 | $-22.00K | $26.00K | $48.00K | -84.62% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-54.00K | $11.00K | $65.00K | -490.91% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |